Recommendations for clinical implementation of blood-based biomarkers for Alzheimer’s disease
(2024) Alzheimer’s and Dementia, . Cited 1 time.
Mielke, M.M.a , Anderson, M.b , Ashford, J.W.c d , Jeromin, A.e , Lin, P.-J.f , Rosen, A.g h , Tyrone, J.i , Vandevrede, L.j , Willis, D.R.k , Hansson, O.l m , Khachaturian, A.S.n , Schindler, S.E.o , Weiss, J.p , Batrla, R.q , Bozeat, S.r , Dwyer, J.R.s , Holzapfel, D.t u , Jones, D.R.q , Murray, J.F.u , Partrick, K.A.t , Scholler, E.t u , Vradenburg, G.t u , Young, D.v , Braunstein, J.B.w , Burnham, S.C.x , de Oliveira, F.F.y , Hu, Y.H.q , Mattke, S.z , Merali, Z.aa , Monane, M.w , Sabbagh, M.N.ab , Shobin, E.ac , Weiner, M.ad , Udeh-Momoh, C.T.a aa
a Department of Epidemiology and Prevention, Wake Forest University School of Medicine, Winston-Salem, United States
b Atrium Health, Charlotte, NC, United States
c Department of Psychiatry and Behavioral Sciences, Stanford University School of Medicine, Stanford, CA, United States
d War Related Illness and Injury Study Center, VA Palo Alto Health Care System, Palo Alto, CA, United States
e ALZpath, Carlsbad, CA, United States
f Center for the Evaluation of Value and Risk in Health Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States
g Palo Alto Veterans Affairs Medical Center, Palo Alto, CA, United States
h Stanford University School of Medicine, Stanford, CA, United States
i Patient Advocate, Sacramento, CA, United States
j Memory and Aging Center, Department of Neurology, University of California, San Francisco, CA, United States
k Department of Family Medicine, Indiana University School of Medicine, Indianapolis, IN, United States
l Clinical Memory Research Unit, Department of Clinical Sciences Malmö, Lund University, Lund, Sweden
m Memory Clinic, Skåne University Hospital, Malmö, Sweden
n The Campaign to Prevent Alzheimer’s Disease, Rockville, MD, United States
o Department of Neurology, Knight Alzheimer’s Disease Research Center, Washington University School of Medicine, St. Louis, MO, United States
p US Department of Health and Human Services, Health Resources and Services Administration, Bureau of Health Workforce, Rockville, MD, United States
q Eisai Inc, Nutley, NJ, United States
r F. Hoffman–La Roche AG, Basel, Switzerland
s Global Alzheimer’s Platform Foundation, Washington, DC, United States
t The Global CEO Initiative on Alzheimer’s Disease, Philadelphia, PA, United States
u Davos Alzheimer’s Collaborative, Philadelphia, PA, United States
v Guidehouse, McLean, VA, United States
w C2N Diagnostics, St. Louis, MO, United States
x Eli Lilly & Co., Indianapolis, IN, United States
y Federal University of São Paulo, São Paulo, Brazil
z The USC Brain Health Observatory, University of Southern California, Los Angeles, CA, United States
aa Brain and Mind Institute, Aga Khan University, Nairobi, Kenya
ab Barrow Neurological Institute, Phoenix, AZ, United States
ac Biogen, Cambridge, MA, United States
ad Departments of Radiology and Biomedical Imaging, Medicine, Psychiatry, and Neurology, University of California, San Francisco, CA, United States
Abstract
Blood-based biomarkers (BBM) for Alzheimer’s disease (AD) are being increasingly used in clinical practice to support an AD diagnosis. In contrast to traditional diagnostic modalities, such as amyloid positron emission tomography and cerebrospinal fluid biomarkers, BBMs offer a more accessible and lower cost alternative for AD biomarker testing. Their unique scalability addresses the anticipated surge in demand for biomarker testing with the emergence of disease-modifying treatments (DMTs) that require confirmation of amyloid pathology. To facilitate the uptake of BBMs in clinical practice, The Global CEO Initiative on Alzheimer’s Disease convened a BBM Workgroup to provide recommendations for two clinical implementational pathways for BBMs: one for current use for triaging and another for future use to confirm amyloid pathology. These pathways provide a standardized diagnostic approach with guidance on interpreting BBM test results. Integrating BBMs into clinical practice will simplify the diagnostic process and facilitate timely access to DMTs for eligible patients. © 2024 The Author(s). Alzheimer’s & Dementia published by Wiley Periodicals LLC on behalf of Alzheimer’s Association.
Author Keywords
Alzheimer’s disease; amyloid; biomarker; blood-based biomarkers; clinical implementation; clinical practice; cognitive impairment; disease-modifying treatment; patient journey; primary care; secondary care
Document Type: Article
Publication Stage: Article in Press
Source: Scopus